ResMed stock: buy or sell?
December 6th, 2019
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases.
Should I buy ResMed stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
These 2 buy setups work for ResMed stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is ResMed stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we detected 6 ratings published for RMD stock in the last 30 days. The general sentiment of these ratings is bullish for RMD stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-29||Goldman Sachs Group||Neutral||Buy|
|2019-4-18||JPMorgan Chase & Co.||Underweight||Neutral|
ResMed stock analysis
ResMed remained steady 0.27% to $150.59 after marking all time highs on Dec/6.
ResMed remained constant 0.27% on Dec 6th and marked a new all time high at $151.60. RMD is soaring again after a 2.73% correction from its last top on Nov/29 at $151.30. On October 25th RMD price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.
Shares of ResMed ended this week at $150.59 after marking a new all time high ($151.60) and gained a slightly good 0.66%. Late October RMD rocketed an extraordinary 9.04% in just one week.
ResMed stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since SMA20d and SMA40w crossed up late June, RMD price climbed $31.19 per share (26.12%). Since price and SMA40w lines crossed up late April, RMD climbed $47.57 (46.18%).
ResMed stock price history
ResMed IPO was on June 2nd, 1995 at $0.66 per share1. Since then, RMD stock surged a 22,716.70%, with a yearly average of 946.50%. If you had invested right after RMD's IPO a $1,000 in ResMed stock in 1995, it would worth $227,167.00 today.
1: Adjusted price after possible price splits or reverse-splits.
ResMed stock historical price chart
RMD stock reached all-time highs on December 6th with a price of $151.60.
ResMed stock price target is $140.00Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we only found 1 price prediction for ResMed stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when ResMed presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, ResMed annual revenues boosted an exceptional 13.23% to $2,340.20 million USD from $2,066.74 marked in 2017. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) depreciated a -3.08% to 13.49%. ResMed presents anual results in June, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, ResMed TTM sales up to were $1,863.01 and income $340.19 M USD. When comparing this TTM figures with the last reported annuality, we can esteem ResMed business evolution since June 2018: Annual turnover up to , compared to lastest yearly report, plummed a chilling -20.39%. In contrary, profit margin (net income/sales) grew at 13.49%.
|2013||$1,510 M||-||$307 M20.3%||-|
|2014||$1,550 M||2.65%||$345 M22.3%||12.42%|
|2015||$1,679 M||8.32%||$353 M21.0%||2.21%|
|2016||$1,839 M||9.52%||$352 M19.2%||-0.14%|
|2017||$2,067 M||12.40%||$342 M16.6%||-2.87%|
|2018||$2,340 M||13.23%||$316 M13.5%||-7.80%|
|TTM||$1,863 M||-20.39%||$340 M18.3%||7.79%|
Quarterly financial resultsResMed reported million in revenues for 2019-Q1, a -100.00% less compared to previous quarter. Reported quarter earnings marked million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was 19.14%. When comparing sales to same quarter last year, ResMed sales marked a spooky correction and collapsed a -100.00%.
|2017-Q1||$514 M||-||$88 M17.1%||-|
|2017-Q2||$557 M||8.26%||$102 M18.3%||15.70%|
|2017-Q3||$524 M||-5.93%||$86 M16.4%||-15.23%|
|2017-Q4||$601 M||14.82%||$10 M1.6%||-88.94%|
|2018-Q1||$592 M||-1.60%||$110 M18.6%||1,055.93%|
|2018-Q2||$624 M||5.41%||$110 M17.6%||-0.29%|
|2018-Q3||$588 M||-5.67%||$106 M18.0%||-3.71%|
|2018-Q4||$651 M||10.68%||$125 M19.1%||17.88%|
ResMed ownershipWhen you are planning to invest in shares of a company, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For ResMed, 1.21% of all outstanding shares are owned by its staff.
In case of ResMed stock, 71.01% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for RMD stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$21.7 B||$4.4 M||$71.6 M||$1.6 B||$8.7 M|
|Total shares||143.8 M||4.0 M||8.5 M||22.0 M||17.8 M|
|Float shares||142.5 M||3.4 M||6.6 M||18.2 M||3.0 M|
|- Institutional holdings (%)||71.0%||11.2%||25.9%||109.7%||0.7%|
|- Insider holdings (%)||1.2%||62.9%||18.5%||1.2%||75.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$150.48 - $151.60|
|Average true range||$2.33|
|50d mov avg||$140.27|
|100d mov avg||$136.18|
|200d mov avg||$122.68|
ResMed performanceTo measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare ResMed to Allied Healthcare Products, Electromed, Inogen, Lianluo Smart, Masimo, Medtronic, Koninklijke Philips and Thermo Fisher Scientific:
|TMOThermo Fisher Sci...||8.57%||13.79%||36.10%|
ResMed competitorsWe chose a few stocks to conform a list of ResMed competitors to check if you are interested in investing in RMD:
- Allied Healthcare Products (AHPI)
- Electromed (ELMD)
- Inogen (INGN)
- Lianluo Smart (LLIT)
- Masimo (MASI)
- Medtronic (MDT)
- Koninklijke Philips (PHG)
- Thermo Fisher Scientific (TMO)
Latest ResMed stock news
- Seeking AlphaProbing ResMed For A Swing TradeMarch 27, 2019
- Seeking AlphaResMed: Positioned For GrowthMarch 26, 2019
- InvestorPlaceResMed Earnings: RMD Stock Plunges on Q2 Revenue MissJanuary 25, 2019